Coya Therapeutics Inc. has released results of a study designed to evaluate the effects of COYA-303 (low dose IL-2 and a GLP-1 receptor agonist) in an established in vivo lipopolysaccharide mouse model of systemic and neuroinflammation. COYA-303 is an investigational proprietary combination for subcutaneous administration, under development for the treatment of diseases driven by chronic and sustained inflammation.